Securities Code: 300529
Bond Code: 123117
Securities Abbreviation: Jianhu Bio
Bond Abbreviation: Jianhu Convertible Bond
Announcement No.: 2026-049
Jianhu Bio-tech Group Co., Ltd.
Announcement on Increasing the Estimated Amount of Routine Related Transactions for 2026
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Jianhu Bio-tech Group Co., Ltd. (hereinafter referred to as the "Company") held the third meeting of the Sixth Board of Directors on August 6, 2026, and reviewed and approved the "Proposal on Increasing the Estimated Amount of Routine Related Transactions for 2026". The relevant matters are hereby explained as follows:
I. Basic Situation of Routine Related Transactions
(I) Overview of Routine Related Transactions
On December 31, 2025, the Company held the thirty-eighth meeting of the Fifth Board of Directors and reviewed and approved the "Proposal on Estimating Routine Related Transactions for 2026". The estimated total amount of routine related transactions between the Company and its subsidiaries and related parties in 2026 was not to exceed RMB 5.81 million (excluding tax).
On April 27, 2026, the Company held the fortieth meeting of the Fifth Board of Directors and reviewed and approved the "Proposal on Confirming Related Transactions in 2025 and Increasing the Estimated Amount of Routine Related Transactions for 2026". According to the Company's actual situation, it was agreed that the estimated amount of routine related transactions between the Company and its subsidiaries for 2026 would be increased by no more than RMB 2.60 million (excluding tax). After this adjustment, the total estimated amount of routine related transactions for 2026 would not exceed RMB 8.41 million (excluding tax). Related directors Dong Fan and Lei Wen recused themselves from voting. This matter has also been reviewed and approved by the Company's Independent Director Special Committee.
On July 17, 2026, the Company held the second meeting of the Sixth Board of Directors and reviewed and approved the "Proposal on Increasing the Estimated Amount of Routine Related Transactions for 2026". According to the Company's actual situation, it was agreed that the estimated amount of routine related transactions between the Company and its subsidiaries for 2026 would be increased by no more than RMB 3.00 million (excluding tax). After this adjustment, the total estimated amount of routine related transactions for 2026 would not exceed RMB 11.41 million (excluding tax). Related directors Dong Fan and Lei Wen recused themselves from voting. This matter has also been reviewed and approved by the Company's Independent Director Special Committee.